PSMA1 Protein

title: PSMA1 Protein

PSMA1 (Proteasome Subunit Alpha Type 1)

Introduction

Psma1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@nguyen2021]

Overview

PSMA1 (Proteasome Subunit Alpha Type 1) encodes the α1 subunit of the 20S proteasome core particle, a crucial component of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) responsible for targeted protein degradation in all eukaryotic cells. In the brain, PSMA1 is expressed in [neurons](/entities/neurons) and glia where it plays essential roles in maintaining [protein homeostasis](/mechanisms/protein-quality-control-network)), clearing misfolded proteins, and regulating synaptic function. Dysfunction of PSMA1 and the proteasome complex is strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [Huntington's disease](/diseases/huntington-disease). [@kikuchi2020]

<div class="infobox infobox-protein"> [@zhang2018]

...

title: PSMA1 Protein

PSMA1 (Proteasome Subunit Alpha Type 1)

Introduction

Psma1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@nguyen2021]

Overview

PSMA1 (Proteasome Subunit Alpha Type 1) encodes the α1 subunit of the 20S proteasome core particle, a crucial component of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) responsible for targeted protein degradation in all eukaryotic cells. In the brain, PSMA1 is expressed in [neurons](/entities/neurons) and glia where it plays essential roles in maintaining [protein homeostasis](/mechanisms/protein-quality-control-network)), clearing misfolded proteins, and regulating synaptic function. Dysfunction of PSMA1 and the proteasome complex is strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [Huntington's disease](/diseases/huntington-disease). [@kikuchi2020]

<div class="infobox infobox-protein"> [@zhang2018]

| Property | Value | [@deng2021]
|----------|-------| [@sitte2020]
| Protein Name | Proteasome Subunit Alpha Type 1 |
| Gene | [PSMA1](/genes/psma1) |
| UniProt ID | [P25786](https://www.uniprot.org/uniprot/P25786) |
| PDB ID | [5MX3](https://www.ebi.ac.uk/pdbe/5MX3) |
| Molecular Weight | 27.6 kDa |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | Proteasome alpha subunit family |
| Expression | Ubiquitous, high in brain |

</div>

Structure

The PSMA1 protein is a 263-amino acid subunit that adopts the classic α/β fold shared by all proteasome subunits. Each subunit contains an N-terminal threonine residue (Thr1) that serves as the catalytic nucleophile for proteolysis.

Quaternary Structure

The 20S proteasome forms a barrel-shaped complex composed of four stacked heptameric rings:

• Outer α-rings: Composed of PSMA1-7, forming the substrate entry gate
• Inner β-rings: Composed of PSMB1-7, containing the proteolytic sites (PSMB5, PSMB6, PSMB7)

The α-rings regulate substrate access through the gated channel mechanism, controlled by regulatory particles (19S/PA700) or proteasome activators (PA28/11S, Blm10/PA200).

Post-Translational Modifications

PSMA1 undergoes various modifications including:

• Phosphorylation (affects proteasome assembly and activity)
• Acetylation (alters substrate recognition)
• Oxidative modifications (can impair function in aging brains)

Normal Function

PSMA1 is essential for proteasome assembly and catalytic function:

Protein Degradation

• Proteolysis: The α-ring contributes to the structural integrity of the proteolytic chamber
• Substrate recognition: PSMA1 contains binding sites for ubiquitin tags
• Gate regulation: Controls entry of substrates into the proteolytic core in response to regulatory particles

Cellular Homeostasis

• Protein quality control: Degrades damaged, oxidized, and misfolded proteins
• Cell cycle regulation: Processes cyclins and cell cycle regulators
• Stress response: Clears stress-induced protein aggregates

Neuronal Specific Functions

• Synaptic protein turnover: Regulates synaptic plasticity through degradation of synaptic proteins
• Neurotransmitter receptor regulation: Controls AMPA and [NMDA receptor](/entities/nmda-receptor) subunit composition
• Axonal transport: Facilitates degradation of transport complex components

Role in Neurodegenerative Diseases

Alzheimer's Disease

Proteasome dysfunction is a hallmark of AD brains:

• Impaired [20S proteasome activity](/mechanisms/ubiquitin-proteasome-system) contributes to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) accumulation
• PSMA1 levels are reduced in AD temporal [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
• Oxidative stress damages PSMA1, creating a vicious cycle of proteasome impairment and protein aggregation
• [Tau](/proteins/tau) oligomers can directly inhibit proteasome function

Parkinson's Disease

• [α-Synuclein](/proteins/alpha-synuclein) oligomers inhibit proteasome activity
• Loss of PSMA1 immunoreactivity in substantia nigra dopaminergic neurons
• Mutations in [parkin](/genes/parkin) (E3 ubiquitin ligase) impair [UPS](/mechanisms/ubiquitin-proteasome-system) function
• Proteasome inhibition leads to dopaminergic neuron death

Amyotrophic Lateral Sclerosis (ALS)

• [TDP-43](/proteins/tdp-43) aggregates overwhelm proteasome capacity
• Mutations in [SOD1](/genes/sod1) linked to proteasome impairment
• Reduced PSMA1 expression in spinal cord motor neurons
• Proteasome dysfunction contributes to aggregate accumulation

Huntington's Disease

• Mutant [huntingtin](/proteins/huntingtin) directly inhibits proteasome function
• PSMA1 levels correlate with disease progression
• Proteasome impairment exacerbates mutant huntingtin aggregation
• UPS dysfunction is an early event in HD pathogenesis

Therapeutic Approaches

Proteasome Modulation

The proteasome is a therapeutic target:

• Proteasome inhibitors: Bortezomib, carfilzomib (FDA-approved for multiple myeloma, neurotoxicity limits CNS use)
• Proteasome activators: Under development for neurodegenerative diseases
• Natural compounds: Flavonoids and polyphenols can enhance proteasome activity

Gene Therapy Approaches

• Viral vector delivery of PSMA1 to restore proteasome function
• CRISPR-based approaches to enhance proteasome assembly
• Small molecules promoting proteasome biogenesis

Combination Strategies

• Proteasome activation + [autophagy](/mechanisms/autophagy) enhancement
• Antioxidant therapy to protect PSMA1 from oxidative damage
• Targeting upstream UPS components ([ubiquitin](/proteins/ubiquitin), E3 ligases)

Experimental Models

Cell Culture

• PSMA1 knockdown in [SH-SY5Y](/cell-types/sh-sy5y-neuroblastoma) cells
• Proteasome inhibition models of neurodegeneration
• Induced [iPSC-derived neurons](/cell-types/ipsc-derived-neurons)

Animal Models

• PSMA1 conditional knockout mice
• Transgenic models with proteasome impairment
• Crossbreeding with [APP/PS1](/mechanisms/app-ps1-mouse) mice

Biochemical Studies

• Cryo-EM structure of neuronal proteasomes
• Proteomic analysis of proteasome substrates
• Activity-based profiling of proteasome function

Biomarkers

Fluid Biomarkers

• Decreased proteasome activity in cerebrospinal fluid (CSF) of AD/PD patients
• PSMA1 levels in [exosomes](/entities/exosomes) as potential marker

Imaging

• PET ligands for proteasome activity (under development)
• Correlates with [tau](/proteins/tau) and [amyloid-beta](/proteins/amyloid-beta) burden

Research Directions

Current Challenges

• Delivery of proteasome modulators across the [blood-brain barrier](/mechanisms/blood-brain-barrier)
• Achieving selective neuronal proteasome activation
• Understanding tissue-specific proteasome regulation

Emerging Areas

• Neuron-specific proteasome isoforms
• Proteasome-phosphodiesterase complexes
• Proteasome regulation by non-coding RNAs

Background

The study of Psma1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [PSMA1 Gene](/genes/psma1)
• [Proteasome](/mechanisms/dopaminergic-neuron-vulnerability)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Autophagy](/mechanisms/autophagy-lysosomal-pathway)
• [Protein Quality Control](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [UniProt P25786](https://www.uniprot.org/uniprot/P25786) — Protein database entry
• [PDB 5MX3](https://www.ebi.ac.uk/pdbe/5MX3) — Crystal structure
• [PubMed: PSMA1 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PSMA1+neurodegeneration) — Literature search

References

[Groll M, et al., Structure of 20S proteasome from yeast at 2.4Å resolution. Nature. 1997;386(6624):463-471 (1997)](https://doi.org/10.1038/386463a0)

[Unknown, Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147 (2015)](https://doi.org/10.1038/emm.2014.117)

[Unknown, Thibaudeau TA, Anderson RT, Smith JR. Proteasome as a therapeutic target in neurodegenerative disease. Curr Pharm Des. 2013;19(18):3260-3274 (2013)](https://pubmed.ncbi.nlm.nih.gov/23431944/)

[Unknown, Nguyen P, Barakat A, Mook-Jung I. Proteasome modulation as a therapeutic approach in Alzheimer's disease. Front Aging Neurosci. 2021;13:630853 (2021)](https://doi.org/10.3389/fnagi.2021.630853)

[Kikuchi M, et al., Proteasome impairment in neural cells by amyloid-beta peptide. J Neurochem. 2020;152(3):381-395 (2020)](https://doi.org/10.1111/jnc.14905)

[Zhang J, et al., alpha-Synuclein and proteasome in Parkinson's disease: a dangerous liaison. J Neural Transm (Vienna). 2018;125(3):461-472 (2018)](https://doi.org/10.1007/s00702-017-1730-9)

[Deng H, et al., TDP-43 pathology in ALS: proteasome impairment and stress granule formation. Acta Neuropathol. 2021;141(2):173-186 (2021)](https://doi.org/10.1007/s00401-020-02217-0)

[Sitte S, et al., Proteasome inhibition leads to early synaptic dysfunction in Huntington's disease. J Neurosci. 2020;40(12):2412-2424 (2020)](https://doi.org/10.1523/JNEUROSCI.2049-19.2020)